Sandbox: sadaf: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 20: Line 20:


'''''To review the complete differential diagnosis of restrictive lung disease, click here.'''''
'''''To review the complete differential diagnosis of restrictive lung disease, click here.'''''
'''Abbreviations''': '''ABG''': Arterial blood gas, '''BAL''': Bronchoalveolar lavage, '''ESR''': Erythrocyte sedimentation rate, '''CRP''': C–reactive protein, '''FVC''': Forced vital capacity, '''RV''': Residual volume, '''FEV1''': Forced expiratory volume during the 1st second, '''DLCO''': Diffusing capacity of the lungs for carbon monoxide, '''O2''': Oxygen, '''TLC''': Total lung capacity, '''PaO2''': Arterial partial pressure of oxygen, '''FiO2''': Fraction of inspired oxygen, '''LDH''': Lactate dehydrogenase, '''CEA''': Carcinoembryonic antigen, '''Anti-GBM antibody''': Anti-glomerular basement membrane antibody, '''A−a gradient''': Alveolar-arterial gradient, '''PAS''': Periodic acid-Schiff stain, '''LAM''': Lymphangiomyomatosis, '''IgE''': Immunoglobulin E, '''ANCA''': Anti-neutrophil cytoplasmic antibody, '''RBC''': Red blood cell, '''ACE''': Angiotensin-converting enzyme


{| class="wikitable"
{| class="wikitable"
Line 419: Line 421:
* ↑ [[CEA]]
* ↑ [[CEA]]
* ↑ [[Surfactant]] protein A, B, and D
* ↑ [[Surfactant]] protein A, B, and D
* [[Anti-glomerular basement membrane antibody|IgG anti−GM−CSF antibodies]] +
* [[Anti-glomerular basement membrane antibody|Anti-GBM antibody]] +
* [[Polycythemia]]
* [[Polycythemia]]
* [[Hypergammaglobulinemia]]
* [[Hypergammaglobulinemia]]
Line 455: Line 457:
| align="center" |−
| align="center" |−
|
|
* Decreased breath sounds
* Decreased [[breath sounds]]
| align="center" |−
| align="center" |−
| align="center" | +
| align="center" | +
|
|
* ↑ Vascular endothelial growth factor−D (VEGF−D)
* ↑ [[Vascular endothelial growth factor|Vascular endothelial growth factor−D]] (VEGF−D)
|
|
* Pneumothorax
* [[Pneumothorax]]
* Chylothorax
* [[Chylothorax]]
* Thin−walled round cystic lesions
* Thin−walled round [[Cyst|cystic]] lesions
|
|
* ↓ FEV1/FVC
* ↓ [[FEV1/FVC ratio|FEV1/FVC]]
|
|
* ↓ PaO2
* ↓ [[Pulmonary gas pressures|PaO2]]
* ↓ O2
* ↓ [[Oxygen|O2]]
|
|
* LAM cells +
* [[LAM]] cells +
|
|
* Lung [[biopsy]]
* Lung [[biopsy]]
Line 488: Line 490:
| align="center" | +
| align="center" | +
|
|
* Decreased breath sounds
* Decreased [[breath sounds]]
| align="center" |−
| align="center" |−
| align="center" |−
| align="center" |−
|
|
* Neutrophilic leukocytosis
* Neutrophilic [[leukocytosis]]
* ↑ Eosinophils
* ↑ [[Eosinophil granulocyte|Eosinophils]]
* Elevated ESR
* Elevated [[Erythrocyte sedimentation rate|ESR]]
* Elevated CRP
* Elevated [[C-reactive protein|CRP]]
* Elevated IgE level
* Elevated [[Immunoglobulin E|IgE]] level
|
|
* Bilateral diffuse mixed ground glass and reticular opacities
* Bilateral diffuse mixed ground glass and reticular opacities
* Small bilateral pleural effusions
* Small bilateral [[Pleural effusion|pleural effusions]]
* Centrilobular nodules and air−space consolidation
* Centrilobular [[Nodule (medicine)|nodules]] and air−space [[Consolidation (medicine)|consolidation]]
|
|
* ↑ FEV1/FVC
* ↑ [[FEV1/FVC ratio|FEV1/FVC]]
* ↓ DLCO
* ↓ [[DLCO]]
|
|
* ↓ PaO2
* ↓ [[Pulmonary gas pressures|PaO2]]
* ↓ O2
* ↓ [[Oxygen|O2]]
|
|
* Eosinophilia 
* [[Eosinophilia]] 
|
|
* Clinical evaluation and investigations
* Clinical evaluation and investigations
Line 530: Line 532:
| align="center" | +
| align="center" | +
|
|
* Neutrophilic leukocytosis
* Neutrophilic [[leukocytosis]]
|
|
* Centrilobular ground−glass or nodular opacities of mid−to−upper zone 
* Centrilobular ground−glass or nodular opacities of mid−to−upper zone 
* Air−trapping
* Air−trapping
|
|
* ↓ FEV1
* ↓ [[FEV1]]
* ↓ FVC
* ↓ [[Vital capacity|FVC]]
|
|
* ↓ PaO2
* ↓ [[Pulmonary gas pressures|PaO2]]
* ↓ O2
* ↓ [[Oxygen|O2]]
|
|
* Lymphocytosis
* [[Lymphocytosis]]
|
|
* Lung [[biopsy]]
* Lung [[biopsy]]
Line 587: Line 589:
| align="center" | +
| align="center" | +
|
|
* Fine crackles
* Fine [[Rales|crackles]]
| align="center" |Peripheral/central
| align="center" |Peripheral/central
| align="center" | +
| align="center" | +
|
|
* Anemia
* [[Anemia]]
* Neutrophilia
* [[Neutrophilia]]
* Elevated ESR
* Elevated [[Erythrocyte sedimentation rate|ESR]]
* Elevated CRP
* Elevated [[C-reactive protein|CRP]]
* Elevated [[Antibody|immunoglobulin]]
* Elevated [[Antibody|immunoglobulin]]
|
|
Line 606: Line 608:
* Granulomata
* Granulomata
|
|
* ↑ FEV1/FVC
* ↑ [[FEV1/FVC ratio|FEV1/FVC]]
|
|
* ↓O2
* ↓ [[Oxygen|O2]]
* ↑CO2
* ↑ CO2
* Respiratory acidosis
* [[Respiratory acidosis]]
|
|
* Mineral dust +
* Mineral dust +
|
|
* History of environmental exposure and imaging
* History of environmental exposure and imaging
* Lung biopsy not required
* Lung [[biopsy]] not required
|-
|-
! colspan="2" style="background:#DCDCDC;" align="center" |Radiation−induced lung injury<ref name="pmid25854336">{{cite journal |vauthors=Giridhar P, Mallick S, Rath GK, Julka PK |title=Radiation induced lung injury: prediction, assessment and management |journal=Asian Pac. J. Cancer Prev. |volume=16 |issue=7 |pages=2613–7 |date=2015 |pmid=25854336 |doi= |url=}}</ref>
! colspan="2" style="background:#DCDCDC;" align="center" |Radiation−induced lung injury<ref name="pmid25854336">{{cite journal |vauthors=Giridhar P, Mallick S, Rath GK, Julka PK |title=Radiation induced lung injury: prediction, assessment and management |journal=Asian Pac. J. Cancer Prev. |volume=16 |issue=7 |pages=2613–7 |date=2015 |pmid=25854336 |doi= |url=}}</ref>
Line 631: Line 633:
| align="center" | +
| align="center" | +
|
|
* Crackles
* [[Rales|Crackles]]
* Pleural rub
* [[Pleural friction rub|Pleural rub]]
* Dullness to percussion
* Dullness to [[percussion]]
| align="center" | +
| align="center" | +
| align="center" |−
| align="center" |−
Line 639: Line 641:
* Nonspecific
* Nonspecific
|
|
* Perivascular haziness to patchy alveolar filling densities
* Perivascular haziness to patchy [[Alveolus|alveolar]] filling densities
* Straight line effect
* Straight line effect
* Pleural effusion
* [[Pleural effusion]]
|
|
* ↓ TLC
* ↓ [[Total lung capacity|TLC]]
* ↓ FVC
* ↓ [[Vital capacity|FVC]]
* ↓ FEV1
* ↓ [[Spirometry|FEV1]]
* ↓ DLCO
* ↓ [[DLCO]]
|
|
* ↓ PaO2
* ↓ [[Pulmonary gas pressures|PaO2]]
* ↓ O2
* ↓ [[Oxygen|O2]]
|
|
* Lymphocytosis
* [[Lymphocytosis]]
|
|
* History of irradiation and clinical presentation
* History of irradiation and clinical presentation
Line 670: Line 672:
| align="center" |−
| align="center" |−
|
|
* Bilateral coarse crepitations
* Bilateral coarse [[crepitations]]
| align="center" |−
| align="center" |−
| align="center" |−
| align="center" |−
|
|
* Anti−GBM antibodies +
* [[Anti-glomerular basement membrane antibody|Anti-GBM antibody]] +
* ANCA +
* [[Anti-neutrophil cytoplasmic antibody|ANCA]] +
* Anemia
* [[Anemia]]
* RBC in the urine
* [[Red blood cell|RBC]] in the urine
|
|
* Pulmonary infiltrates
* Pulmonary infiltrates
|
|
* ↑ DLCO
* ↑ [[DLCO]]
|
|
* Normal
* Normal
Line 687: Line 689:
* NA
* NA
|
|
* Kidney biopsy
* Kidney [[biopsy]]
|-
|-
! style="background:#DCDCDC;" align="center" |Idiopathic pulmonary hemosiderosis<ref name="KhorashadiWu2015">{{cite journal|last1=Khorashadi|first1=L.|last2=Wu|first2=C.C.|last3=Betancourt|first3=S.L.|last4=Carter|first4=B.W.|title=Idiopathic pulmonary haemosiderosis: spectrum of thoracic imaging findings in the adult patient|journal=Clinical Radiology|volume=70|issue=5|year=2015|pages=459–465|issn=00099260|doi=10.1016/j.crad.2014.11.007}}</ref>
! style="background:#DCDCDC;" align="center" |Idiopathic pulmonary hemosiderosis<ref name="KhorashadiWu2015">{{cite journal|last1=Khorashadi|first1=L.|last2=Wu|first2=C.C.|last3=Betancourt|first3=S.L.|last4=Carter|first4=B.W.|title=Idiopathic pulmonary haemosiderosis: spectrum of thoracic imaging findings in the adult patient|journal=Clinical Radiology|volume=70|issue=5|year=2015|pages=459–465|issn=00099260|doi=10.1016/j.crad.2014.11.007}}</ref>
Line 703: Line 705:
| align="center" |−
| align="center" |−
|
|
* Crackles
* [[Rales|Crackles]]
| align="center" | −
| align="center" | −
| align="center" |−
| align="center" |−
|
|
* Iron deficiency anemia
* [[Iron deficiency anemia]]
* ↑ Plasma bilirubin  
* ↑ Plasma [[bilirubin]]
* ↑ Urinary excretion of urobilinogen
* ↑ Urinary excretion of [[urobilinogen]]
* ↑ Reticulocytes
* ↑ [[Reticulocytes]]
* Fecal occult blood
* [[Fecal occult blood]] +
* Normal serum ferritin
|
|
* Mid to lower zone alveolar opacities
* Mid to lower zone [[Alveolus|alveolar]] opacities
* Multiple honeycomb cysts
* Multiple honeycomb [[Cyst|cysts]]
|
|
* ↓ TLC
* ↓ [[Lung volumes|TLC]]
* ↓ FVC
* ↓ [[Vital capacity|FVC]]
* ↓ FEV1
* ↓ [[Spirometry|FEV1]]
* ↑ FEV1/FVC
* ↑ [[FEV1/FVC ratio|FEV1/FVC]]
* ↑ DLCO
* ↑ [[DLCO]]
|
|
* ↓ O2
* ↓ [[Oxygen|O2]]
* ↓ CO2
* ↓ CO2
|
|
* ↑  Hemosiderin−laden macrophages
* ↑  [[Hemosiderin]]−laden [[Macrophage|macrophages]]
|
|
* Clinical evaluation and investigations
* Clinical evaluation and investigations
Line 744: Line 745:
| align="center" | +
| align="center" | +
|
|
* Decreased breath sounds
* Decreased [[breath sounds]]
| align="center" |−
| align="center" |−
| align="center" |−
| align="center" |−
|
|
* Anemia
* [[Anemia]]
* Leukocytosis
* [[Leukocytosis]]
|
|
* Diffuse alveolar haemorrhage
* Diffuse [[Alveolus|alveolar]] haemorrhage
|
|
* ↓ FEV1/FVC
* ↓ [[FEV1/FVC ratio|FEV1/FVC]]
|
|
* ↓ [[Oxygen|O2]]
* ↓ [[Oxygen|O2]]
|
|
* Diffuse alveolar haemorrhage
* Diffuse [[Alveolus|alveolar]] haemorrhage
|
|
* Diagnosis of exclusion
* Diagnosis of exclusion
Line 803: Line 804:
| align="center" | −
| align="center" | −
|
|
* Crackles
* [[Rales|Crackles]]
* Wheezing
* [[Wheeze|Wheezing]]
* Decreased breath sounds
* Decreased [[breath sounds]]
| align="center" | +
| align="center" | +
| align="center" | −
| align="center" | −
|
|
* Hypercalciuria 
* [[Hypercalciuria]] 
* Hypercalcemia
* [[Hypercalcemia]]
* High ACE
* High [[Angiotensin-converting enzyme|ACE]]
* Hypergammaglobulinemia
* [[Hypergammaglobulinemia]]
*
|
|
* Hilar adenopathy
* [[Hilar lymphadenopathy|Hilar adenopathy]]
* Reticular opacities
* Reticular opacities
* Pneumothorax
* [[Pneumothorax]]
* Pleural thickening
* [[Pleural cavity|Pleural]] thickening
* Chylothorax
* [[Chylothorax]]
* Pulmonary hypertension
* [[Pulmonary hypertension]]
|
|
* ↓ TLC
* ↓ [[Lung volumes|TLC]]
* ↓ FVC
* ↓ [[Vital capacity|FVC]]
* ↓ FEV1
* ↓ [[Spirometry|FEV1]]
* ↑ FEV1/FVC
* ↑ [[FEV1/FVC ratio|FEV1/FVC]]
* ↓ DLCO
* ↓ [[DLCO]]
|
|
* ↓ O2
* ↓ [[Oxygen|O2]]
* ↓ CO2
* ↓ CO2
* Respiratory acidosis
* [[Respiratory acidosis]]
|
|
* Lymphocytosis 
* [[Lymphocytosis]] 
* Elevated adenosine deaminase
* Elevated [[adenosine deaminase]]
* D−dimer +
* [[D-dimer]] +
|
|
* Clinical evaluation and investigations
* Clinical evaluation and investigations
Line 853: Line 853:
| align="center" | −
| align="center" | −
|
|
* Crackles
* [[Rales|Crackles]]
| align="center" | −
| align="center" | −
| align="center" | −
| align="center" | −
|
|
* Antineutrophil cytoplasmic autoantibody (ANCA) +
* [[Anti-neutrophil cytoplasmic antibody|ANCA]] +
* Anemia
* [[Anemia]]
* Leukocytosis
* [[Leukocytosis]]
* Thrombocytosis
* [[Thrombocytosis]]
* Elevated ESR
* Elevated [[Erythrocyte sedimentation rate|ESR]]
* Elevated CRP
* Elevated [[C-reactive protein|CRP]]
* Elevated creatinine
* Elevated [[creatinine]]
* Urine protein +
* Urine [[protein]] +
* Hematuria 
* [[Hematuria]] 
|
|
* Cavitate nodules
* Cavitate [[Nodule (medicine)|nodules]]
* Ground−glass opacity
* Ground−glass opacity
* Consolidation
* [[Consolidation (medicine)|Consolidation]]
* Pleural effusion
* [[Pleural effusion]]
* Hilar adenopathy
* [[Hilar lymphadenopathy|Hilar adenopathy]]
|
|
* ↓ FEV1/FVC
* ↓ [[FEV1/FVC ratio|FEV1/FVC]]
|
|
* ↓ [[Oxygen|O2]]
* ↓ [[Oxygen|O2]]
Line 895: Line 895:
| align="center" | −
| align="center" | −
|
|
* Scattered wheezing
* Scattered [[Wheeze|wheezing]]
| align="center" | −
| align="center" | −
| align="center" | −
| align="center" | −
|
|
* Eosinophilia
* [[Eosinophilia]]
* Elevated IgE titers
* Elevated [[Immunoglobulin E|IgE]] titers
* Anti−myeloperoxidase (MPO) antineutrophil cytoplasmic antibodies (ANCA) +
* [[Anti-neutrophil cytoplasmic antibody|ANCA]] +
|
|
* Areas of parenchymal opacification
* Areas of parenchymal opacification
* Mixed interstitial patchy alveolar opacities
* Mixed interstitial patchy [[Alveolus|alveolar]] opacities
|
|
* ↓ Vt
* ↓ [[Lung volumes|TLC]]


* ↑ RV
* ↑ [[Residual volume|RV]]
|
|
* Normal
* Normal
|
|
* Eosinophilia 
* [[Eosinophilia]] 
|
|
* Lung [[biopsy]]
* Lung [[biopsy]]
Line 930: Line 930:
| align="center" | −
| align="center" | −
|
|
* Scattered wheezing
* Scattered [[Wheeze|wheezing]]
| align="center" | −
| align="center" | −
| align="center" |−
| align="center" |−
|
|
* Eosinophilia
* [[Eosinophilia]]
* Elevated IgE titers
* Elevated [[Immunoglobulin E|IgE]] titers
* Elevated circulating IgE antibodies to Aspergillus species
* Elevated circulating IgE antibodies to [[Aspergillus]] species
|
|
* Upper zone single or multiple pulmonary nodules 
* Upper zone single or multiple pulmonary [[Nodule (medicine)|nodules]] 
* Consolidation
* [[Consolidation (medicine)|Consolidation]]
* Atelectasis
* [[Atelectasis]]
|
|
* ↓ FEV1/FVC
* ↓ [[FEV1/FVC ratio|FEV1/FVC]]
|
|
* Normal
* Normal
|
|
* Eosinophilia 
* [[Eosinophilia]] 
|
|
* Lung [[biopsy]]
* Lung [[biopsy]]
Line 968: Line 968:
| align="center" |−
| align="center" |−
|
|
* Epstein−Barr virus (EBV) serology +
* [[Epstein Barr virus|Epstein-Barr virus]] (EBV) serology +
|
|
* Mid to lower zone multiple poorly defined nodules
* Mid to lower zone multiple poorly defined [[Nodule (medicine)|nodules]]
* Diffuse reticular abnormalities
* Diffuse reticular abnormalities
|
|
* Normal
* Normal
|
|
* ↓ O2
* ↓ [[Oxygen|O2]]
* Chronic respiratory alkalosis
* Chronic [[respiratory alkalosis]]
|
|
* Normal
* Normal
Line 996: Line 996:
| align="center" | −
| align="center" | −
|
|
* Crackles
* [[Rales|Crackles]]
| align="center" | −
| align="center" | −
| align="center" | −
| align="center" | −
Line 1,003: Line 1,003:
|
|
* Tracheobronchial infiltration
* Tracheobronchial infiltration
* Persistent pleural effusions
* Persistent [[Pleural effusion|pleural effusions]]
* Parenchymal nodules (amyloidomas)
* Parenchymal [[Nodule (medicine)|nodules]]
|
|
* ↓ FEV1/FVC
* ↓ [[FEV1/FVC ratio|FEV1/FVC]]
|
|
* ↓ [[Oxygen|O2]]
* ↓ [[Oxygen|O2]]

Revision as of 16:38, 8 March 2018

Malabsorption

Home

Overview

Classification

Infection
Structural defect
Digestive failure
Systemic disease
Iatrogenic

Differentiating Malabsorption from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]

Overview

Classification

Pathophysiology

  • Interstitial lung disease is a group of disorders that involve pulmonary parenchyma.
  • The exact pathogenesis of these disorders are not fully understood.
  • There are multiple initiating factors that cause pulmonary injury. However, immunopathogenic responses of lung tissue are quite similar.
  • There are two major histopathologic patterns in response to lung injury which include:
    • Inflammation and fibrosis pattern
    • Granulomatous pattern

Differentiating Interstitial Lung Disease from other Diseases

To review the complete differential diagnosis of dyspnea, click here.

To review the complete differential diagnosis of hemoptysis, click here.

To review the complete differential diagnosis of restrictive lung disease, click here.

Abbreviations: ABG: Arterial blood gas, BAL: Bronchoalveolar lavage, ESR: Erythrocyte sedimentation rate, CRP: C–reactive protein, FVC: Forced vital capacity, RV: Residual volume, FEV1: Forced expiratory volume during the 1st second, DLCO: Diffusing capacity of the lungs for carbon monoxide, O2: Oxygen, TLC: Total lung capacity, PaO2: Arterial partial pressure of oxygen, FiO2: Fraction of inspired oxygen, LDH: Lactate dehydrogenase, CEA: Carcinoembryonic antigen, Anti-GBM antibody: Anti-glomerular basement membrane antibody, A−a gradient: Alveolar-arterial gradient, PAS: Periodic acid-Schiff stain, LAM: Lymphangiomyomatosis, IgE: Immunoglobulin E, ANCA: Anti-neutrophil cytoplasmic antibody, RBC: Red blood cell, ACE: Angiotensin-converting enzyme

Disease Clinical manifestation Investigations
History Symptoms Physical examination Lab findings Imaging Pulmonary function test Bronchoscopy and BAL Gold standard
Duration Age Gender Family history Smoking history Environmental exposure HIV Dyspnea Cough Wheezing Chest pain Tachypnea   Auscultation Cyanosis Clubbing Spirometry ABG
Idiopathic pulmonary fibrosis[1] Chronic 60−70 years old Men + + ± + Dry + + + +
  • Bibasilar, peripheral reticular abnormalities
  • Focal honeycomb cyst formation
  • Traction bronchiectasis
  • Diagnosis of exclusion 
  • Lung biopsy
Idiopathic nonspecific interstitial pneumonia[2] Acute/Chronic 50−60 years old Female + + + + + + ±
  • Normal
  • Nonspecific
  • Lung biopsy and multidisciplinary approach
Cryptogenic organising pneumonia[3] Acute/subacute 50−60 years old Both ± + Dry
Disease History Symptoms Physical examination Lab findings Imaging Pulmonary function test Bronchoscopy and BAL Gold standard
Duration Age Gender Family history Smoking history Environmental exposure HIV Dyspnea Cough Wheezing Chest pain Tachypnea   Auscultation Cyanosis Clubbing Spirometry ABG
Acute interstitial pneumonia (Hamman−Rich syndrome)[4] Acute 50−60 years old Both + + +
  • N/A
Lymphocytic interstitial pneumonia[5] Subacute 30−40 years old Female ± + + + + +
Respiratory bronchiolitis−interstitial lung disease[6] Subacute 30−40 years old Both + + Dry +
  • Inspiratory high−pitched rhonchi
  • Fine, bibasilar end−inspiratory crackles
  • Nonspecific 
  • Diffuse or patchy ground glass opacities in a mosaic pattern 
  • Fine nodules 
  • Air trapping
  • Clinical evaluation and investigations
Desquamative interstitial pneumonia[7][8] Chronic 40−50 years old Both + + Dry +
  • Fine, bibasilar end−inspiratory crackles
  • Nonspecific 
  • Ground glass opacities without the peripheral reticular and reticulonodular opacities
Disease History Symptoms Physical examination Lab findings Imaging Pulmonary function test Bronchoscopy and BAL Gold standard
Duration Age Gender Family history Smoking history Environmental exposure HIV Dyspnea Cough Wheezing Chest pain Tachypnea   Auscultation Cyanosis Clubbing Spirometry ABG
Pulmonary Langerhans cell granulomatosis[9] Chronic 20−40 years old Both + + ± Dry + +
  • Unremarkable
  • Nonspecific 
  • Normal
Pulmonary alveolar proteinosis[10][11] Acute/chronic 40−50 years old Male + + + + + + + +
  • Bbilateral perihilar and basilar alveolar opacities without air−bronchograms
  • "Bat wing" distribution
  • Intralobular thickening
  • Diffuse ground−glass opacities
Pulmonary lymphangioleiomyomatosis[12] Acute/chronic 30−40 years old Female + + + Bloody + + +
Eosinophilic pneumonia[13] Acute/chronic 20−40 years old Male + Dry + + +
  • Clinical evaluation and investigations
Hypersensitivity pneumonitis[14] Acute/subacute/chronic 40−60 years old Both ± + + Dry/productive + + + +
  • Centrilobular ground−glass or nodular opacities of mid−to−upper zone 
  • Air−trapping
Disease History Symptoms Physical examination Lab findings Imaging Pulmonary function test Bronchoscopy and BAL Gold standard
Duration Age Gender Family history Smoking history Environmental exposure HIV Dyspnea Cough Wheezing Chest pain Tachypnea   Auscultation Cyanosis Clubbing Spirometry ABG
Occupational lung disease[15] Chronic Elderly Male + + + ± + + + + Peripheral/central +
  • Mineral dust +
  • History of environmental exposure and imaging
  • Lung biopsy not required
Radiation−induced lung injury[16] Subacute/chronic Any age Both + + Dry + + + +
  • Nonspecific
  • History of irradiation and clinical presentation
Pulmonary hemorrhage syndromes Goodpasture syndrome[17] Chronic All ages Male + ± ± Bloody ±
  • Pulmonary infiltrates
  • Normal
  • NA
Idiopathic pulmonary hemosiderosis[18] Acute/subacute/chronic Children − 10 years old Both + ± + Bloody + +
  • O2
  • ↓ CO2
  • Clinical evaluation and investigations
Isolated pulmonary capillaritis[19] Chronic 40−60 years old Both + ± + Bloody + + +
  • Diagnosis of exclusion
Disease History Symptoms Physical examination Lab findings Imaging Pulmonary function test Bronchoscopy and BAL Gold standard
Duration Age Gender Family history Smoking history Environmental exposure HIV Dyspnea Cough Wheezing Chest pain Tachypnea   Auscultation Cyanosis Clubbing Spirometry ABG
Sarcoidosis[20] Acute/subacute/chronic 20−40 years old Female + ± ± + + ± +
  • Clinical evaluation and investigations
Granulomatous vasculitides Granulomatosis with polyangiitis (Wegener)[21] Chronic Elderly Both + + + + ±
  • Alveolar hemorrhage
Eosinophilic granulomatosis with polyangiitis (Churg Strauss)[22] Chronic 40−50 years old Both + + +
  • Areas of parenchymal opacification
  • Mixed interstitial patchy alveolar opacities
  • Normal
Bronchocentric granulomatosis[23] Chronic 30−70 years old Both ± ± + ±
  • Normal
Pulmonary lymphomatoid granulomatosis[24] Chronic 30−50 years old Male + + + +
  • Normal
  • Mid to lower zone multiple poorly defined nodules
  • Diffuse reticular abnormalities
  • Normal
  • Normal
Amyloidosis[25][26] Subacute/chronic 50−70 years old Male + Bloody +
  • Congophilia with apple−green birefringence under polarized light
  • Normal
Disease History Symptoms Physical examination Lab findings Imaging Pulmonary function test Bronchoscopy and BAL Gold standard
Duration Age Gender Family history Smoking history Environmental exposure HIV Dyspnea Cough Wheezing Chest pain Tachypnea   Auscultation Cyanosis Clubbing Spirometry ABG

Diagnosis

  • There are multiple laboratory tests that might be helpful to ascertain or rule out the diagnosis of interstitial lung disease.
Condition Disease Test
All patients with suspicious interstitial lung disease Complete blood count and differential
Liver function tests Alanine aminotransferase (ALT, SGPT)
Aspartate aminotransferase (AST, SGOT)
Alkaline phosphatase
Renal function tests Urinalysis
Blood urea nitrogen (BUN)
Creatinine (Cr)
Suspicious of systemic rheumatic disease RA Serology Anti−cyclic citrullinated peptide (Anti−CCP)
SLE Serology Anti−double stranded (ds) DNA antibodies
Amyopathic dermatomyositis Serology Anti−melanoma differentiation−associated gene 5 (MDA−5)
Nonspecific Serology Antinuclear antibody (ANA)
Serology Rheumatoid factor (RF)
Serology Anti−neutrophil cytoplasmic antibody (ANCA)
Enzyme Creatine kinase (CK), aldolase
Mechanic hands Myositis Myositis−associated antibodies Anti−tRNA synthetases Jo−1
Anti−tRNA synthetases PL−7
Anti−tRNA synthetases PL−12
Sicca features or positive anti−extractable nuclear antigen (ENA) Sjögren’s syndrome Serology Anti−RO (SS−A)
Serology Anti−La (SS−B)
Mixed connective tissue disease  Serology Anti−ribonucleoprotein (RNP)
IgG4−related disease Serology Serum IgG4
Severe GERD or sclerodactyly Limited systemic scleroderma Serology Anti−centromere
Systemic scleroderma Serology Anti−topoisomerase I (anti−Scl−70)
Dyspnea Heart failure Enzyme Brain natriuretic peptide (BNP)
Pulmonary hypertension N−terminal proBNP (NT−proBNP)
Anemia and/or hemoptysis Coagulopathies Coagulation studies
Goodpasture syndrome Serology Anti−glomerular basement membrane (GBM) antibodies
Antiphospholipid syndrome  Serology Antiphospholipid antibodies
Idiopathic pulmonary hemosiderosis Serology Serum IgA endomysial or tissue transglutaminase antibodies 
Mediastinal lymphadenopathy Multiple myeloma Serum protein electrophoresis
Beryllium exposure Berylliosis Peripheral blood beryllium lymphocyte proliferation test
Risk factors for HIV HIV ELISA
Western blot test

Occupational lung disease

For more information about occupational lung disease, click here.

Drug−induced lung injury

  • Medications that might cause interstitial lung disease include:[28]
Antimicrobial Agents Anti−Inflammatory Agents Biological Agents Cardiovascular Agents Immunomodulator agents Antineoplastic agents Miscellaneous
  • Amphotericin B
  • Doripenem
  • Ethambutol
  • Isoniazid
  • Minocycline
  • Nitrofurantoin
  • Sulfasalazine
  • Abatacept 
  • Aspirin
  • Azathioprine
  • Cyclophosphamide
  • Etanercept
  • Gold
  • Infliximab
  • Interleukin−1 blockers (anakinra)
  • Leflunomide
  • Methotrexate
  • Nonsteroidal anti−inflammatory drugs
  • Penicillamine
  • Rituximab (anti−CD20 monoclonal antibody)
  • Sulfasalazine
  • Thalidomide
  • Adalimumab
  • Alemtuzumab
  • Alpha interferon
  • Bevacizumab
  • Cetuximab
  • Etanercept 
  • Rituximab
  • Tocilizumab
  • Trastuzumab
  • ACE inhibitors
  • Amiodarone
  • Anticoagulants
  • Beta blockers
  • Flecainide
  • Hydrochlorothiazide
  • Procainamide
  • Statins
  • Tocainide
  • Azathioprine
  • Bleomycin
  • Bortezomib
  • Busulfan
  • Carmustine (BCNU)
  • Chlorambucil
  • Colony−stimulating factors
  • Crizotinib
  • Cyclophosphamide
  • Cytarabine
  • Cytosine arabinoside
  • Deferoxamine
  • Docetaxel
  • Doxorubicin
  • Eribulin
  • Erlotinib
  • Etoposide (VP−16)
  • Fludarabine
  • Flutamide
  • Gefitinib
  • Gemcitabine
  • Hydroxyurea
  • Imatinib
  • Interferons
  • Lomustine (CCNU)
  • Melphalan
  • Methotrexate
  • Methyl−CCNU
  • Mitomycin−C
  • Nilutamide
  • Nitrosoureas
  • Olsalazine
  • Paclitaxel
  • Panitumumab
  • Procarbazine
  • Semustine (Methyl−CCNU)
  • Sorafenib
  • Thalidomide
  • Vinblastine
  • Zinostatin
  • Bacille Calmette−Guerin (BCG)
  • Bromocriptine
  • Carbamazepine
  • Cabergolide
  • Methysergide
  • L−tryptophan
  • Penicillamine
  • Phenytoin
  • Talc

Radiation−induced lung injury

  • Pulmonary injury following radiation is directly related to duration and dose of radiation.
  • There are early and late reaction in pulmonary tissues to radiation. 
  • Early pulmonary reaction to radiation usually occurs in 4 to 12 weeks following irradiation. 
  • Late fibrotic response usually occurs 6 to 12 months following irradiation.

Smoking related interstitial lung disease

  • Desquamative interstitial pneumonia
  • Respiratory bronchiolitis–associated interstitial lung disease
  • Pulmonary Langerhans cell granulomatosis

Idiopathic interstitial pneumonias

  • Major idiopathic interstitial pneumonias
    • Idiopathic pulmonary fibrosis
    • Idiopathic nonspecific interstitial pneumonia
    • Respiratory bronchiolitis−interstitial lung disease
    • Desquamative interstitial pneumonia
    • Cryptogenic organising pneumonia
    • Acute interstitial pneumonia
  • Rare idiopathic interstitial pneumonias
    • Idiopathic lymphoid interstitial pneumonia
    • Idiopathic pleuroparenchymal fibroelastosis
  • Unclassifiable idiopathic interstitial pneumonias
  • For more information about Idiopathic interstitial pneumonia, click here.
  • For more information about Cryptogenic organizing pneumonia, click here.
  • For more information about idiopathic pulmonary fibrosis, click here.

Pulmonary alveolar proteinosis

For more information about pulmonary alveolar proteinosis, click here. 

Lymphocytic infiltrative disorders

  • Lymphocytic interstitial pneumonitis
  • Pulmonary lymphomatoid granulomatosis

For more information about lymphocytic interstitial pneumonitis, click here.

Pulmonary lymphangioleiomyomatosis

  • For more information about pulmonary lymphangioleiomyomatosis, click here.

Pulmonary hemorrhage syndromes

  • Goodpasture syndrome
  • Idiopathic pulmonary hemosiderosis
  • Isolated pulmonary capillaritis

Granulomatous lung response

  • Hypersensitivity pneumonitis 
  • Sarcoidosis
  • Granulomatous vasculitides
    • Granulomatosis with polyangiitis (Wegener)
    • Eosinophilic granulomatosis with polyangiitis (ChurgStrauss)
  • Bronchocentric granulomatosis

For more information about hypersensitivity pneumonitis, click here.

Interstitial lung disease associated connective tissue diseases

  • Systemic lupus erythematosus
  • Rheumatoid arthritis
  • Ankylosing spondylitis
  • Systemic sclerosis
  • Sjögren syndrome
  • Polymyositis/dermatomyositis

Interstitial lung disease associated with inherited diseases

  • Tuberous sclerosis
  • Neurofibromatosis
  • Niemann−Pick disease
  • Gaucher disease
  • Hermansky−Pudlak syndrome

Interstitial lung disease associated with gastrointestinal or liver diseases

  • Crohn disease
  • Primary biliary cirrhosis
  • Chronic active hepatitis
  • Ulcerative colitis

Interstitial lung disease associated with graft−versus−host disease

  • Bone marrow transplantation
  • Solid organ transplantation

References

  1. Poletti, Venerino; Ravaglia, Claudia; Buccioli, Matteo; Tantalocco, Paola; Piciucchi, Sara; Dubini, Alessandra; Carloni, Angelo; Chilosi, Marco; Tomassetti, Sara (2013). "Idiopathic Pulmonary Fibrosis: Diagnosis and Prognostic Evaluation". Respiration. 86 (1): 5–12. doi:10.1159/000353580. ISSN 1423-0356.
  2. Travis, William D.; Hunninghake, Gary; King, Talmadge E.; Lynch, David A.; Colby, Thomas V.; Galvin, Jeffrey R.; Brown, Kevin K.; Chung, Man Pyo; Cordier, Jean-François; du Bois, Roland M.; Flaherty, Kevin R.; Franks, Teri J.; Hansell, David M.; Hartman, Thomas E.; Kazerooni, Ella A.; Kim, Dong Soon; Kitaichi, Masanori; Koyama, Takashi; Martinez, Fernando J.; Nagai, Sonoko; Midthun, David E.; Müller, Nestor L.; Nicholson, Andrew G.; Raghu, Ganesh; Selman, Moisés; Wells, Athol (2008). "Idiopathic Nonspecific Interstitial Pneumonia". American Journal of Respiratory and Critical Care Medicine. 177 (12): 1338–1347. doi:10.1164/rccm.200611-1685OC. ISSN 1073-449X.
  3. Mehrian, P.; Doroudinia, A.; Rashti, A.; Aloosh, O.; Dorudinia, A. (2017). "High-resolution computed tomography findings in chronic eosinophilic vs. cryptogenic organising pneumonia". The International Journal of Tuberculosis and Lung Disease. 21 (11): 1181–1186. doi:10.5588/ijtld.16.0723. ISSN 1027-3719.
  4. Parambil, Joseph; Mukhopadhyay, Sanjay (2012). "Acute Interstitial Pneumonia (AIP): Relationship to Hamman-Rich Syndrome, Diffuse Alveolar Damage (DAD), and Acute Respiratory Distress Syndrome (ARDS)". Seminars in Respiratory and Critical Care Medicine. 33 (05): 476–485. doi:10.1055/s-0032-1325158. ISSN 1069-3424.
  5. Panchabhai, Tanmay S.; Farver, Carol; Highland, Kristin B. (2016). "Lymphocytic Interstitial Pneumonia". Clinics in Chest Medicine. 37 (3): 463–474. doi:10.1016/j.ccm.2016.04.009. ISSN 0272-5231.
  6. Sieminska, Alicja; Kuziemski, Krzysztof (2014). "Respiratory bronchiolitis-interstitial lung disease". Orphanet Journal of Rare Diseases. 9 (1). doi:10.1186/s13023-014-0106-8. ISSN 1750-1172.
  7. Ryu, Jay H.; Myers, Jeffrey L.; Capizzi, Stephen A.; Douglas, William W.; Vassallo, Robert; Decker, Paul A. (2005). "Desquamative Interstitial Pneumonia and Respiratory Bronchiolitis-Associated Interstitial Lung Disease". Chest. 127 (1): 178–184. doi:10.1378/chest.127.1.178. ISSN 0012-3692.
  8. Craig, P J; Wells, A U; Doffman, S; Rassl, D; Colby, T V; Hansell, D M; du Bois, R M; Nicholson, A G (2004). "Desquamative interstitial pneumonia, respiratory bronchiolitis and their relationship to smoking". Histopathology. 45 (3): 275–282. doi:10.1111/j.1365-2559.2004.01921.x. ISSN 0309-0167.
  9. Blakley, Matthew P.; Dutcher, Janice P.; Wiernik, Peter H. (2018). "Pulmonary Langerhans cell histiocytosis, acute myeloid leukemia, and myelofibrosis in a large family and review of the literature". Leukemia Research. 67: 39–44. doi:10.1016/j.leukres.2018.01.011. ISSN 0145-2126.
  10. Carrington JM, Hershberger DM. PMID 29493933. Missing or empty |title= (help)
  11. Kiani, Arda; Parsa, Tahereh; Adimi Naghan, Parisa; Dutau, Hervé; Razavi, Fatemeh; Farzanegan, Behrooz; Pourabdollah Tootkaboni, Mahsa; Abedini, Atefeh (2018). "An eleven-year retrospective cross-sectional study on pulmonary alveolar proteinosis". Advances in Respiratory Medicine. 86 (1): 7–12. doi:10.5603/ARM.2018.0003. ISSN 2543-6031.
  12. Xu, Kai-Feng; Lo, Bee Hong (2014). "Lymphangioleiomyomatosis: differential diagnosis and optimal management". Therapeutics and Clinical Risk Management: 691. doi:10.2147/TCRM.S50784. ISSN 1178-203X.
  13. Bernheim, Adam; McLoud, Theresa (2017). "A Review of Clinical and Imaging Findings in Eosinophilic Lung Diseases". American Journal of Roentgenology. 208 (5): 1002–1010. doi:10.2214/AJR.16.17315. ISSN 0361-803X.
  14. Miller, Ross; Allen, Timothy Craig; Barrios, Roberto J.; Beasley, Mary Beth; Burke, Louise; Cagle, Philip T.; Capelozzi, Vera Luiza; Ge, Yimin; Hariri, Lida P.; Kerr, Keith M.; Khoor, Andras; Larsen, Brandon T.; Mark, Eugene J.; Matsubara, Osamu; Mehrad, Mitra; Mino-Kenudson, Mari; Raparia, Kirtee; Roden, Anja Christiane; Russell, Prudence; Schneider, Frank; Sholl, Lynette M.; Smith, Maxwell Lawrence (2018). "Hypersensitivity Pneumonitis A Perspective From Members of the Pulmonary Pathology Society". Archives of Pathology & Laboratory Medicine. 142 (1): 120–126. doi:10.5858/arpa.2017-0138-SA. ISSN 0003-9985.
  15. Sirajuddin, Arlene; Kanne, Jeffrey P. (2009). "Occupational Lung Disease". Journal of Thoracic Imaging. 24 (4): 310–320. doi:10.1097/RTI.0b013e3181c1a9b3. ISSN 0883-5993.
  16. Giridhar P, Mallick S, Rath GK, Julka PK (2015). "Radiation induced lung injury: prediction, assessment and management". Asian Pac. J. Cancer Prev. 16 (7): 2613–7. PMID 25854336.
  17. DeVrieze BW, Hurley JA. PMID 29083697. Missing or empty |title= (help)
  18. Khorashadi, L.; Wu, C.C.; Betancourt, S.L.; Carter, B.W. (2015). "Idiopathic pulmonary haemosiderosis: spectrum of thoracic imaging findings in the adult patient". Clinical Radiology. 70 (5): 459–465. doi:10.1016/j.crad.2014.11.007. ISSN 0009-9260.
  19. Thompson, Gwen; Klecka, Mary; Roden, Anja C.; Specks, Ulrich; Cartin-Ceba, Rodrigo (2016). "Biopsy-proven pulmonary capillaritis: A retrospective study of aetiologies including an in-depth look at isolated pulmonary capillaritis". Respirology. 21 (4): 734–738. doi:10.1111/resp.12738. ISSN 1323-7799.
  20. Li, Cheng-Wei; Tao, Ru-Jia; Zou, Dan-Feng; Li, Man-Hui; Xu, Xin; Cao, Wei-Jun (2018). "Pulmonary sarcoidosis with and without extrapulmonary involvement: a cross-sectional and observational study in China". BMJ Open. 8 (2): e018865. doi:10.1136/bmjopen-2017-018865. ISSN 2044-6055.
  21. Greco A, Marinelli C, Fusconi M, Macri GF, Gallo A, De Virgilio A, Zambetti G, de Vincentiis M (June 2016). "Clinic manifestations in granulomatosis with polyangiitis". Int J Immunopathol Pharmacol. 29 (2): 151–9. doi:10.1177/0394632015617063. PMC 5806708. PMID 26684637.
  22. Greco A, Rizzo MI, De Virgilio A, Gallo A, Fusconi M, Ruoppolo G, Altissimi G, De Vincentiis M (April 2015). "Churg-Strauss syndrome". Autoimmun Rev. 14 (4): 341–8. doi:10.1016/j.autrev.2014.12.004. PMID 25500434.
  23. Myers, Jeffrey L. (1989). "Bronchocentric Granulomatosis". Chest. 96 (1): 3–4. doi:10.1378/chest.96.1.3. ISSN 0012-3692.
  24. Ankita, Grover; Shashi, Dhawan (2016). "Pulmonary Lymphomatoid Granulomatosis- a Case Report with Review of Literature". Indian Journal of Surgical Oncology. 7 (4): 484–487. doi:10.1007/s13193-016-0525-1. ISSN 0975-7651.
  25. Khoor, Andras; Colby, Thomas V. (2017). "Amyloidosis of the Lung". Archives of Pathology & Laboratory Medicine. 141 (2): 247–254. doi:10.5858/arpa.2016-0102-RA. ISSN 0003-9985.
  26. Milani, Paolo; Basset, Marco; Russo, Francesca; Foli, Andrea; Palladini, Giovanni; Merlini, Giampaolo (2017). "The lung in amyloidosis". European Respiratory Review. 26 (145): 170046. doi:10.1183/16000617.0046-2017. ISSN 0905-9180.
  27. Castranova V, Vallyathan V (2000). "Silicosis and coal workers' pneumoconiosis". Environ Health Perspect. 108 Suppl 4: 675–84. PMC 1637684. PMID 10931786.
  28. Schwaiblmair, Martin (2012). "Drug Induced Interstitial Lung Disease". The Open Respiratory Medicine Journal. 6 (1): 63–74. doi:10.2174/1874306401206010063. ISSN 1874-3064.